US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
445 deals · US$333bndisclosed · Healthcare · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| May 2026 | Anagram Therapeutics | – | – | Stake | Announced | – | Biotech+2 | Goodwin (sell-side) |
| May 2026 | Catalyst Pharmaceuticals | – | Angelini Pharma S.p.A. | Acquisition | Pending | 4,100.0 | Pharma+1 | J.P. Morgan (sell-side)Kirkland & Ellis (sell-side)Akerman (sell-side)Centerview Partners (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Hogan Lovells Cadwalader (buy-side)Gatti Pavesi Bianchi Ludovici (buy-side) |
| May 2026 | CDMO and Cell Solutions businesses of Charles River Laboratories | Charles River Laboratories International | GI Partners | Asset sale | Completed | – | Pharma Services+2 | Moelis & Company (buy-side)Ropes & Gray (buy-side) |
| May 2026 | Health Elements AI | – | Medisolv | Acquisition | Announced | – | Healthcare Software+1 | Gibson Dunn (buy-side) |
| May 2026 | Lilac Software | – | Medisolv | Acquisition | Announced | – | Healthcare Software+2 | Gibson Dunn (buy-side) |
| May 2026 | Perfuse Therapeutics | – | Bayer | Acquisition | Announced | 300.0 | Biotech+2 | Goodwin (sell-side) |
| May 2026 | Cross Country Healthcare | – | Knox Lane | Acquisition | Completed | 437.0 | Healthcare Staffing | BofA Securities (sell-side)Davis Polk (sell-side)MTS Health Partners (buy-side)Kirkland & Ellis (buy-side) |
| May 2026 | Candid Therapeutics | – | UCB | Acquisition | Announced | 2,200.0 | Biotech+1 | LazardCooley (sell-side) |
| May 2026 | Esperion Therapeutics | – | ARCHIMED | Acquisition | Pending | 1,100.0 | Pharma+1 | Latham & WatkinsCenterview Partners (sell-side)Goodwin (sell-side)Moelis & Company (buy-side)Sidley Austin (buy-side) |
| May 2026 | Vastian | – | Bregal Sagemount | Stake | Announced | – | Healthcare Software+1 | Kirkland & Ellis (sell-side)Baird (sell-side) |
| May 2026 | EqualizeRCM | – | Carlyle | Acquisition | Completed | – | Healthcare Services+1 | TripleTreeLatham & Watkins (buy-side) |
| May 2026 | Regenity Biosciences | – | Cinven | Stake | Announced | – | Medtech+1 | Baird (sell-side) |
| May 2026 | LimmaTech Biologics AG | – | Eli Lilly and Company | Acquisition | Pending | 780.0 | Biotech | Goodwin (sell-side)Kirkland & Ellis (buy-side) |
| May 2026 | HealthEZ | – | Horizon Mutual Holdings | Acquisition | Completed | – | Healthcare Services+1 | TripleTree |
| May 2026 | Replay | – | LEO Pharma | Acquisition | Announced | 50.0 | Biotech+2 | Latham & Watkins (buy-side) |
| May 2026 | SPR Therapeutics | – | Medtronic | Acquisition | Announced | 650.0 | Medtech | Latham & Watkins (sell-side) |
| May 2026 | PathAI | – | Roche | Acquisition | Pending | 750.0 | Healthcare Software+2 | Latham & Watkins (sell-side)Davis Polk (buy-side) |
| May 2026 | Estia Health | Bain Capital | Stonepeak | Acquisition | Completed | – | Healthcare Services | Gresham (sell-side)Allens (sell-side)Barrenjoey (sell-side)MinterEllison (buy-side) |
| Apr 2026 | vVARDIS Holding AG | – | – | Stake | Announced | – | Medtech | Sidley Austin (buy-side) |
| Apr 2026 | KalVista Pharmaceuticals | – | Chiesi Group | Acquisition | Completed | 1,900.0 | Pharma+2 | Centerview Partners (sell-side)Kirkland & Ellis (sell-side)Fenwick & West (sell-side)Jefferies (sell-side)Lazard (buy-side)Ropes & Gray (buy-side) |
| Apr 2026 | Shionogi-Apnimed Sleep Science | Apnimed | Shionogi & Co. | Acquisition | Announced | 100.0 | Pharma+1 | Goodwin (sell-side) |
| Apr 2026 | Emalex Biosciences | – | Teva Pharmaceuticals | Acquisition | Announced | 700.0 | Pharma+1 | Centerview Partners (sell-side)Bradley Arant Boult Cummings (sell-side)Evercore (buy-side)Faegre Drinker Biddle & Reath (buy-side) |
| Apr 2026 | Naveris | – | CareDx | Acquisition | Announced | 160.0 | Diagnostics+1 | J.P. Morgan (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side)Goldman Sachs (buy-side)Fenwick & West (buy-side) |
| Apr 2026 | Ajax Therapeutics | – | Eli Lilly and Company | Acquisition | Announced | 2,300.0 | Biotech+2 | Cooley (sell-side)Kirkland & Ellis (sell-side)Ropes & Gray (buy-side) |
| Apr 2026 | XOMA Royalty | – | Ligand Pharmaceuticals | Acquisition | Completed | 739.0 | Specialty finance and leasing+2 | Leerink Partners (sell-side)H.C. Wainwright & Co. (sell-side)Gibson Dunn (sell-side)Stifel (buy-side)Citi (buy-side)Paul Hastings (buy-side)Collected Strategies (buy-side) |
| Apr 2026 | Organon & Co. | – | Sun Pharmaceutical Industries | Acquisition | Announced | 11,750.0 | Pharma | Morgan Stanley (sell-side)Goldman Sachs (sell-side)Sullivan & Cromwell (sell-side)Cyril Amarchand Mangaldas (sell-side)J.P. Morgan (buy-side)Jefferies (buy-side)White & Case (buy-side)AZB & Partners (buy-side) |
| Apr 2026 | CathWorks | – | Medtronic | Acquisition | Announced | 585.0 | Medtech+1 | Goodwin (sell-side) |
| Apr 2026 | TruBridge | – | Inventurus Knowledge Solutions | Acquisition | Announced | – | Healthcare Software+1 | Solomon Partners (sell-side)Sullivan & Cromwell (sell-side)Maynard Nexsen (sell-side)Cyril Amarchand Mangaldas (sell-side)Willkie Farr & Gallagher (sell-side)J.P. Morgan (buy-side)Citi (buy-side)Katten Muchin Rosenman (buy-side)Shardul Amarchand Mangaldas & Co (buy-side) |
| Apr 2026 | Kashiv BioSciences | – | Amneal Pharmaceuticals | Acquisition | Completed | 375.0 | Biotech+2 | J.P. Morgan (sell-side)Holland & Knight (sell-side)Goldman Sachs (buy-side)Richards, Layton & Finger (buy-side)Simpson Thacher & Bartlett (buy-side)Boston Consulting Group (buy-side) |
| Apr 2026 | Bonsai Health | – | ModMed | Acquisition | Announced | – | Healthcare Software+1 | Sidley Austin (buy-side) |
| Apr 2026 | Cumberland FDA-approved commercial products and related assets | Cumberland Pharmaceuticals | Nuvo Pharmaceuticals (Ireland) DAC | Asset sale | Pending | 100.0 | Pharma | VelocityHealth Securities (sell-side)Baker Donelson (sell-side)Kirkland & Ellis (buy-side) |
| Apr 2026 | Certara Regulatory and Medical Writing business | Certara | Veristat | Asset sale | Announced | 135.0 | Pharma Services+1 | Perella Weinberg Partners (sell-side)Troutman Pepper Locke (sell-side)Guggenheim Securities (buy-side)McDermott Will & Schulte (buy-side) |
| Apr 2026 | Sila Realty Trust | – | Blue Owl Real Estate Capital LLC affiliates | Acquisition | Completed | 2,400.0 | REITs+1 | BofA Securities (sell-side)Hogan Lovells Cadwalader (sell-side)Venable (sell-side)Citi (buy-side)Truist Securities (buy-side)Newmark (buy-side)Kirkland & Ellis (buy-side)Dechert (buy-side) |
| Apr 2026 | Kelonia Therapeutics | – | Eli Lilly and Company | Acquisition | Announced | 7,000.0 | Biotech+2 | Goodwin (sell-side)Jefferies (sell-side)Kirkland & Ellis (buy-side) |
| Apr 2026 | Neurona Therapeutics | – | UCB | Acquisition | Announced | 650.0 | Biotech+2 | Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side) |
| Apr 2026 | Robocath | – | Stereotaxis | Acquisition | Announced | – | Medtech+1 | Goodwin (sell-side) |
| Apr 2026 | Avanos Medical | – | AIP | Acquisition | Completed | 1,272.0 | Medtech | J.P. Morgan (sell-side)Alston & Bird (sell-side)UBS (sell-side)Joele Frank, Wilkinson Brimmer Katcher (sell-side)Sidley Austin (buy-side)Ropes & Gray (buy-side)Baker Botts (buy-side)Guggenheim Securities (buy-side) |
| Apr 2026 | CrossBridge Bio | – | Eli Lilly and Company | Acquisition | Announced | 300.0 | Biotech+2 | Cooley (sell-side) |
| Apr 2026 | Obsidian Therapeutics | – | Galera Therapeutics | Merger | Completed | 413.5 | Biotech+2 | Goodwin (sell-side)Sidley Austin (buy-side)Leerink Partners (sell-side)Lucid Capital Markets (buy-side) |
| Apr 2026 | Healthcare Linen Services Group | York Private Equity | The Sterling Group | Acquisition | Completed | – | Industrial Services+1 | BofA Securities (sell-side)KeyBanc Capital Markets (sell-side)Sidley Austin (sell-side)Stephens (buy-side)Latham & Watkins (buy-side)Weil, Gotshal & Manges (buy-side) |
| Apr 2026 | US sales and distribution rights for seven Assertio branded products | Assertio Holdings | Cosette Pharmaceuticals | Asset sale | Announced | – | Pharma | Gibson Dunn (sell-side) |
| Apr 2026 | OFFOR Health | – | Havencrest Capital Management | Acquisition | Completed | – | Healthcare Services | Cascadia Capital (buy-side)Ziegler (sell-side)Bass, Berry & Sims (buy-side) |
| Apr 2026 | Bentec Medical | Greyrock Capital Group | Avista Healthcare Partners | Acquisition | Completed | – | Medtech+1 | Piper Sandler (sell-side)McGuireWoods (sell-side)Willkie Farr & Gallagher (buy-side) |
| Apr 2026 | Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup) | Assertio Holdings | Cosette Pharmaceuticals | Asset sale | Completed | 35.0 | Pharma | Moelis & Company (sell-side)Gibson Dunn (sell-side) |
| Apr 2026 | MethodOne by Computalogic | – | Qualifacts | Asset sale | Announced | – | Healthcare Software+1 | Orrick (buy-side) |
| Apr 2026 | Worldwide rights to Kenalog | Bristol-Myers Squibb | Subsidiary of Piramal Pharma | Asset sale | Announced | 35.0 | Pharma | Goodwin (buy-side) |
| Apr 2026 | Assertio Holdings | – | Zydus Worldwide DMCC | Acquisition | Announced | 166.4 | Pharma | Moelis & Company (sell-side)Gibson Dunn (sell-side)Longacre Square Partners (sell-side)Paul, Weiss (buy-side) |
| Apr 2026 | d2i | – | ESO Solutions | Acquisition | Announced | – | Healthcare Software+1 | Kirkland & Ellis (buy-side) |
| Apr 2026 | Tubulis | EQT Life Sciences (LSP 7 fund) | Gilead Sciences | Acquisition | Announced | 3,150.0 | Biotech+2 | Goodwin (sell-side)J.P. Morgan (sell-side)CMS (sell-side)Centerview Partners (buy-side)Allen & Company (buy-side)Covington & Burling (buy-side)Arnold & Porter (buy-side)Venable (buy-side) |
| Apr 2026 | Soleno Therapeutics | – | Neurocrine Biosciences | Acquisition | Completed | 2,900.0 | Biotech+2 | Centerview Partners (sell-side)Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goodwin (sell-side)Goldman Sachs (buy-side)Cooley (buy-side) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built